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Aim: MicroRNAs (miRNAs) are small noncoding RNAs that function as oncogene or tumor suppressors. The single nucleotide 
polymorphisms in miRNAs potentially can alter miRNA-binding sites on target genes as well as affecting miRNAs expression. The 
present study aimed to evaluate the impact of miR-608 rs4919510 C>G variant on breast cancer (BC) risk. Materials and Me thods: 
This case-control study conducted on 160 women with BC and 192 age-matched healthy women. Genotyping of miR-
608 rs4919510 was done using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: 
Our findings showed that GC genotype significantly decreased the risk of BC (odds ratio (OR) = 0.49, 95% confidence interval 
(CI) 0.28–0.88, p = 0.018) compared to CC genotype. Furthermore the G allele decreased the risk of BC (OR = 0.53, 
95%CI 0.30–0.92, p = 0.024). No significant association was found between miR-609 genotypes and clinicopathological charac-
teristics of BC patients (p > 0.05). Conclusion: Our findings indicate that miR-608 polymorphism might be associated with decreased 
risk of BC in an Iranian subpopulation. Further large-scale studies with different ethnicities are needed to verify our findings.
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Breast cancer (BC) is one of the most prevalent types 
of cancer in women. It is a major public and global health 
problem and accounts for 14% of total cancer deaths 
worldwide annually [1]. Similarly, BC is among the most 
common malignancies amongst Iranian women [2]. Al-
though causes of BC are not yet completely understood, 
genetic factors are indicated to play key roles in the 
pathogenesis and progress of this malignancy [3–8].
MicroRNAs (miRNAs) are a highly conserved class 
of small (~ 22 nucleotides), endogenous, non-coding 
RNAs suppressing posttranscriptional gene expres-
sion by base pairing with their target messenger RNAs 
(mRNAs) and inducing either translational repression 
or mRNA degradation [9–11]. Loss of heterozygos-
ity in the 10q24 locus has been described in numeral 
of human cancers [12–15]. Hsa-mir-608 lies within 
an intron of SEMA4G in this region. Several single 
nucleotide polymorphisms in the sequences of pre-
miRNAs such as miR-196a2 (rs11614913 T>C), miR–
499 (rs3746444 A>G), and miR-125a (rs12975333 G>T) 
were associated with significantly increased risks 
of BC in some but not all studies [7, 16–18].
It has been proposed that rs4919510 C>G variant 
in miR-608 can alter its binding to target genes [19]. 
The expected targets of miR-608 include insulin recep-
tor (INSR), interleukin-1 alpha (IL1A), growth hormone 
receptor (GHR), and TP53 [19].
Several studies examined the impact of miR-
608 rs4919510 C>G on the risk of various cancers, 
but the results were inconsistent [20–26]. To the best 
of our knowledge, limited studies evaluated associa-
tion between miR-608 rs4919510 polymorphism and 
BC risk [21, 27, 28]. So, this case-control study was 
designed to assess the possible association between 
miR-608 rs4919510 polymorphism and susceptibility 
to BC in an Iranian subpopulation.
MATERIALS AND METHODS
This case-control study was done on 160 BC patients 
and 192 age-matched healthy women with no history 
of cancer of any type (as the control group) in Zahe-
dan, southeast Iran. Ethical approvals for recruitment 
were taken from local Ethics Committee of Zahedan 
University of Medical Sciences, and informed consent 
was obtained from all patients and healthy individu-
als. The study design and enrolment procedure were 
described previously [29–31].
Genotyping of miR-608 rs4919510 C>G was done 
by PCR–RFLP methods. Briefly, forward and reverse 
primers were 5´-TCTGGCTAGGTAATGGCTCC-3´ and 
5´-GCATCTGTGGCCTTCCATGA-3´, respectively. The 
PCR product was digested by PvuII restriction en-
zyme (Fermentas). G allele digested and produced 
242-bp and 117-bp pattern, while C allele undigested 
and produced 359-bp fragment (Figure).
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Figure. Photograph of miR608 rs4919510 C>G polymorphism 
using PCR-RFLP method. G allele digested by PvuII restriction 
enzyme and produced 242-bp and 117-bp pattern, while C allele 
was undigested (359-bp fragment). M — DNA marker; lanes 
1 and 3 — CC; lane 2 and 4 — CG
Statistical analysis. Statistical analysis was done 
using statistical package SPSS 20 software. The 
categorical and continuous data were analyzed using 
χ2 and t-test, respectively. The association between 
genotypes and BC were assessed by computing the 
odds ratio (OR) and 95% confidence intervals (CI) from 
logistic regression analyses. A p-value of < 0.05 was 
considered to be statistically significant.
RESULTS
The study group consisted of 160 BC patients with 
an average age of 48.5 ± 10.8 years and 192 healthy 
women with a mean age of 49.5 ± 12.4 years. No sig-
nificant difference was found between the groups 
regarding age (p = 0.424).
The genotype and allele frequencies of miR-
608 rs4919510 C>G polymorphism in BC patients and 
healthy women are shown. Our findings showed that 
rs4919510 variant significantly decreased the risk of BC 
(OR = 0.49, 95% CI 0.28–0.88, p = 0.018, CG vs CC) 
(Table 1). Moreover, the G allele significantly decreased 
the risk of BC (OR = 0.53, 95% CI 0.30–0.92, p = 0.024) 
compared with C allele. No significant association was 
found between miR-609 genotypes and clinicopatho-
logical characteristics of BC patients (p > 0.05).
Table 1. Association of miR-608 rs4919510 C>G polymorphism and risk 
of BC
miR608  
rs4919510 C>G Case, n (%)
Control,  
n (%) OR (95% CI) p
Genotype
CC 140 (87.5) 149 (77.6) 1.00 −
GC 20 (12.5) 43 (22.4) 0.49 (0.28–0.88) 0.018
GG 0 (0.0) 0 (0.0) − −
Allele
C 300 (93.8) 341 (88.8) 1.00 −
G 20 (6.2) 43 (11.2) 0.53 (0.30–0.92) 0.024
Hardy — Weinberg equilibrium (HWE) was as-
sessed by chi-square test. The genotype of miR-
608 rs4919510 polymorphism in both controls and 
cases were in HWE (χ2 = 3.05, p = 0.081 and χ2 = 0.71, 
p = 0.399, respectively).
As shown in Table 2, miR-608 rs4919510 polymor-
phism was not associated with clinicopathological 
characteristics, including age, tumor size, tumor 
stage, tumor grade, lymph node metastasis, estrogen 
and progesterone receptors (ER, PgR) status, and 
human epidermal growth factor receptor 2 (HER2/
neu) (p > 0.05).
Table 2. Association between miR-608 rs4919510 C>G variant and clini-
copathological characteristics of BC patients
Variables miR-608 rs4919510 pCC CG
Age 0.943
≤ 50 82 12
> 50 58 8
Tumor size, cm 0.467
≤ 2 49 9
> 2 86 11
Lymph node metastasis status 0.793
Yes 83 13
No 39 5
Grade 0.811
I 23 4
II 71 10
III + IV 19 4
Stage 0.994
I 24 3
II 55 8
III 39 6
IV 21 3
Histology 0.611
Ductal carcinoma 91 12
Others 43 8
ER 0.799
Positive 82 12
Negative 50 6
PgR 0.311
Positive 78 8
Negative 54 10
HER2/neu 0.244
Positive 74 7
Negative 65 12
DISCUSSION
In the present study we inspected the impact 
of miR-608 rs4919510 variant on the risk of BC risk 
in a sample of Iranian population. Our data showed that 
rs4919510 polymorphism significantly decreased the risk 
of BC in our population. We found no significant associa-
tion between miR-608 rs4919510 genotypes and clinico-
pathological characteristics of BC patients (p > 0.05).
Huang et al. [27] identified that the mir-
608 rs4919510 was not associated with BC risk, but 
CG/GG genotypes were specifically associated with 
increased risk of HER2-positive BC (OR = 1.97, 95% 
CI 1.34–22.90). Variant G allele was the risk allele 
with OR of 1.62 (95% CI 1.23–22.15). They found that 
patients carrying GG-genotype also had larger HER2-
positive tumors. They concluded that rs4919510 poly-
morphism in mature miR-608 may influence HER2-
positive BC risk and proliferation of tumor. Jiao 
et al. [21] have found no significant association between 
miR-608 rs4919510 polymorphism and BC survival 
in Chinese population. Dai et al. [28] observed that 
miR-608 rs4919510 was not associated with BC risk.
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In summary, our findings proposed that miR-
608 rs4919510 polymorphism decreased the risk 
of BC in a sample of Iranian population. However, 
we found no significant association between this 
variant and the clinicopathological characteristics 
of BC patients. Population based studies with larger 
sample sizes with different ethnicities and long-term 
follow-up are required to confirm our finding.
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